Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study

Trial Profile

Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Midodrine (Primary) ; Pyridostigmine
  • Indications Orthostatic hypotension
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Aug 2017 Primary endpoint (Change in Orthostatic BP Drop) has been met as per the results published in the Neurology
    • 09 Aug 2017 Results published in the Neurology
    • 02 Mar 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top